This meta-analysis is the most comprehensive review of the literature evaluating the efficacy of dual therapy with Peg-IFN α-2a or α-2b plus ribavirin versus triple therapy with Peg-IFN+ribavirin and a first-generation NS3 protease inhibitor, telaprevir or boceprevir, in treating therapy-naïve or relapser anti-HIV-negative patients with HCV-1 CHC. This evidence concerns the gene KRAS and cryohydrocytosis.